Eric Chen just laid out a timeline faster than most expected. The Injective CEO told The Block that a US-listed INJ ETF could potentially launch before 2027.
There are currently two ETF applications tied to INJ: the 21Shares Injective ETF and the Canary Staked INJ ETF. The latter's name already signals its angle — it's targeting staking yield rather than simply tracking the spot price.
Eric Chen didn't specify what basis he used for this timeline, and both applications are still under review, having not yet received approval from US regulators.
